// App-Quantinova.ai

: Blinatumomab Is Cost-Effective Compared to Standard Chemotherapy for Children with High Risk Relapses of Acute Lymphoblastic Leukemia: A Cost-Effectiveness Analysis Using Population-Based Healthcare Data

Researchers

Presenter

  • Petros Pechlivanoglou

Principal Investigators

  • Linda Luu

  • Qing LI

  • Paul J. Gibson

  • Uma H. Athale

  • Mylene Bassal

  • Vicky R. Breakey

  • Serina Patel

  • Jason Pole

  • Rinku Sutradhar

  • Laura Wheaton

  • Nicole Mittmann

  • Sumit Gupta

Medical Centers

  • McMaster Children's Hospital, HAMILTON, Canada

  • Kingston General Hospital, Kingston, Canada

  • University of Queensland, Brisbane, AUS

  • Institute for Clinical Evaluative Sciences, Toronto, Canada

  • Hospital for Sick Children Research Institute, Toronto, Canada

  • Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada

  • Cancer Research Program, ICES, Toronto, Canada

  • Cancer Research Program, Institute for Clinical Evaluative Sciences, Toronto, Canada

  • Division of Pediatric Hematology/Oncology, McMaster University, Hamilton, Canada

  • London Health Sciences Centre, London, Canada

  • Children's Hospital of Eastern Ontario, Ottawa, CAN

  • Sunnybrook Research Institute, Toronto, Canada

Locations

  • Canada

  • Australia

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Blinatumomab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved